Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
VAV3 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
20 July 2026
A visual target evaluation report for VAV3, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
VAV2 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
20 July 2026
A visual target evaluation report for VAV2, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
VAV1 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
20 July 2026
A visual target evaluation report for VAV1, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
USP30 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
20 July 2026
A visual target evaluation report for USP30, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
Latest Hotspot
8 min read
Artiva Biotherapeutics Company BD Opportunity Scan Report 2026: Pipeline, Deals, Partnering Shortlist, and Outreach Priorities
20 July 2026
Artiva Biotherapeutics 2026 BD opportunity scan covering pipeline assets, deal precedents, financial signals, IP risk and a prioritized partnering shortlist.
8 min read
USP28 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
20 July 2026
A visual target evaluation report for USP28, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
Latest Hotspot
8 min read
Adicet Bio Company BD Opportunity Scan Report 2026: Pipeline, Deals, Partnering Shortlist, and Outreach Priorities
20 July 2026
Adicet Bio 2026 BD opportunity scan covering pipeline assets, deal precedents, financial signals, IP risk and a prioritized partnering shortlist.
8 min read
USP22 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
20 July 2026
A visual target evaluation report for USP22, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
Latest Hotspot
8 min read
Adaptimmune Therapeutics Company BD Opportunity Scan Report 2026: Pipeline, Deals, Partnering Shortlist, and Outreach Priorities
20 July 2026
Adaptimmune Therapeutics 2026 BD opportunity scan covering pipeline assets, deal precedents, financial signals, IP risk and a prioritized partnering shortlist.
Latest Hotspot
8 min read
Bicycle Therapeutics Company BD Opportunity Scan Report 2026: Pipeline, Deals, Partnering Shortlist, and Outreach Priorities
20 July 2026
Bicycle Therapeutics 2026 BD opportunity scan covering pipeline assets, deal precedents, financial signals, IP risk and a prioritized partnering shortlist.
Latest Hotspot
8 min read
ADC Therapeutics Company BD Opportunity Scan Report 2026: Pipeline, Deals, Partnering Shortlist, and Outreach Priorities
20 July 2026
ADC Therapeutics 2026 BD opportunity scan covering pipeline assets, deal precedents, financial signals, IP risk and a prioritized partnering shortlist.
8 min read
USP18 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
20 July 2026
A visual target evaluation report for USP18, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.